Qiagen (QGEN) AGM 2024 summary

Opening remarks and agenda

• The meeting was held in Venlo, Netherlands, on June 21, 2024, covering the 2023 calendar year and forward-looking statements for 2024–2028.

• Chair welcomed attendees, introduced board members and auditors, and outlined meeting procedures and voting rights for 221.8 million shares, with over 170.7 million represented.

Financial performance review

• 2023 net sales reached $1.97 billion, an 8% decline overall, but non-COVID product sales grew 8% at constant exchange rates.

• Adjusted EPS was $2.09, exceeding the outlook, and adjusted operating margin was 26.9%.

• Operating income was $410 million, adjusted operating income $529 million, and free cash flow $310 million.

• R&D investment increased to 10.1% of sales, supporting new product development.

• Diagnostic solutions, especially QuantiFERON, saw 24% CER growth, while sample technologies and PCR products declined.

Board and executive committee updates

• Two new Supervisory Board members, Eva van Pelt and Bert van Meurs, were introduced, bringing extensive industry experience.

• All current Supervisory Board members and Managing Directors were reappointed for new terms through the next AGM.